Publications by authors named "Martin Pass"

Claim this Profile
M
Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9.
Scott J Hughes, Wojciech J Stec, Colin T R Davies, David McGarry, Alicia Williams, Martin Pass

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Kurt G Pike, Thomas A Hunt, Bernard Barlaam, David Benstead, Elaine Cadogan, Martin Pass

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Martin Pass

Clin Cancer Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.
Aurelija Jucaite, Per Stenkrona, Zsolt Cselényi, Serena De Vita, Nuria Buil-Bruna, Martin Pass

Neuro Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with -Mutant, ER-Positive Metastatic Breast Cancer.
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, Eva M Ciruelos, Ingrid A Mayer, Martin Pass

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER Invasive Breast Cancer (STAKT).
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Martin Pass

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, Gemma N Jones, Adina M Hughes, Martin Pass

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
Jeremy Karlin, Jasmine Allen, Syed F Ahmad, Gareth Hughes, Victoria Sheridan, Martin Pass

Mol Cancer Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
Bernard Barlaam, Elaine Cadogan, Andrew Campbell, Nicola Colclough, Allan Dishington, Martin Pass

ACS Med Chem Lett· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Stephen T Durant, Li Zheng, Yingchun Wang, Kan Chen, Lingli Zhang, Martin Pass

Sci Adv· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in -Mutated Breast and Gynecologic Cancers.
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L Bedard, Martin Pass

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Kurt G Pike, Bernard Barlaam, Elaine Cadogan, Andrew Campbell, Yingxue Chen, Martin Pass

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT Inhibition in Solid Tumors With AKT1 Mutations.
David M Hyman, Lillian M Smyth, Mark T A Donoghue, Shannon N Westin, Philippe L Bedard, Martin Pass

J Clin Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Sébastien L Degorce, Scott Boyd, Jon O Curwen, Richard Ducray, Christopher T Halsall, Martin Pass, Sarah Pass

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Sylvie M Guichard, Jon Curwen, Teeru Bihani, Celina M D'Cruz, James W T Yates, Martin Pass

Mol Cancer Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.
Kurt G Pike, Jeff Morris, Linette Ruston, Sarah L Pass, Ryan Greenwood, Martin Pass

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Kurt G Pike, Karine Malagu, Marc G Hummersone, Keith A Menear, Heather M E Duggan, Sarah L Pass, Martin Pass

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Matt Addie, Peter Ballard, David Buttar, Claire Crafter, Gordon Currie, Martin Pass

J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Vibha Oza, Susan Ashwell, Lynsie Almeida, Patrick Brassil, Jason Breed, Martin Pass

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.
Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, Simon T Barry, Darren A E Cross, Martin Pass

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.
Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, Simon T Barry, Darren A E Cross, Martin Pass

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Barry R Davies, Hannah Greenwood, Phillippa Dudley, Claire Crafter, De-Hua Yu, Martin Pass

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.
Vibha Oza, Susan Ashwell, Patrick Brassil, Jason Breed, Jaychandran Ezhuthachan, Martin Pass

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Jason G Kettle, Simon Brown, Claire Crafter, Barry R Davies, Phillippa Dudley, Martin Pass

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Mark J Anderton, Howard R Mellor, Alex Bell, Claire Sadler, Martin Pass

Toxicol Pathol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis